FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis

Multiple Sclerosis

Volumn 21, Issue 14, 2015, Pages 1811-1822

  Luessi, Felix ^a   Kraus, Stefan ^a   Trinschek, Bettina ^a   Lerch, Steffen ^a   Ploen, Robert ^a   Paterka, Magdalena ^a   Roberg, Torsten ^a   Poisa Beiro, Laura ^a   Klotz, Luisa ^a   Wiendl, Heinz ^a   Bopp, Tobias ^a   Jonuleit, Helmut ^a   Jolivel, Valérie ^a   Zipp, Frauke ^a   Witsch, Esther ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

cytokine; dendritic cell; Fingolimod; immunotherapy; monocyte; multiple sclerosis

Indexed keywords

CD86 ANTIGEN; FINGOLIMOD; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYCLOPHOSPHAMIDE; INTERLEUKIN 10; NATALIZUMAB; TUMOR NECROSIS FACTOR; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LYMPH NODE; MALE; MONOCYTE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PROTEIN CONTENT; PROTEIN SECRETION; RETROSPECTIVE STUDY; T LYMPHOCYTE; UPREGULATION; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION ASSAY; EVALUATION AND FOLLOW UP; FLOW CYTOMETRY; GENE EXPRESSION; GENOTYPE PHENOTYPE CORRELATION; IMMUNOLOGICAL TOLERANCE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; BLOOD; DRUG EFFECTS; YOUNG ADULT;

ADULT; CYTOKINES; DENDRITIC CELLS; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 84948144040     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515574895     Document Type: Article

References (36)

1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
2. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
3. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
4. Idzko M, Panther E, Corinti S, et al. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J 2002; 16: 625-627.
5. Okamoto H, Takuwa N, Gonda K, et al. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem 1998; 273: 27104-27110.
6. Maeda Y, Matsuyuki H, Shimano K, et al. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 2007; 178: 3437-3446.
7. Muller H, Hofer S, Kaneider N, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 2005; 35: 533-545.
8. Lidington EA, McCormack AM, Yacoub MH, et al. The effects of monocytes on the transendothelial migration of T lymphocytes. Immunology 1998; 94: 221-227.
9. Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011; 76: 1214-1221.
10. Lewis ND, Haxhinasto SA, Anderson SM, et al. Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3. J Immunol 2013; 190: 3533-3540.
11. Jolivel V, Luessi F, Masri J, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013; 136: 1048-1066.
12. Kraus SH, Luessi F, Trinschek B, et al. Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. Int Immunopharmacol 2014; 18: 347-357.
13. Hiscott J, Marois J, Garoufalis J, et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993; 13: 6231-6240.
14. Noor S, Wilson EH,. Role of C-C chemokine receptor type 7 and its ligands during neuroinflammation. J Neuroinflammation 2012; 9: 77.
15. Kramer S, Binder E, Loof T, et al. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. Am J Physiol Renal Physiol 2009; 297: F218-227.
16. Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13: 935-943.
17. Lutz MB, Schuler G,. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23: 445-449.
18. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002; 52: 421-428.
19. Papenfuss TL, Powell ND, McClain MA, et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol 2011; 186: 3346-3355.
20. Galicia-Rosas G, Pikor N, Schwartz JA, et al. A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner. J Immunol 2012; 189: 3700-3706.
21. Zeng X, Wang T, Zhu C, et al. Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro. PLoS One 2012; 7: e34830.
22. Leech MD, Barr TA, Turner DG, et al. Cutting edge: IL-6-dependent autoimmune disease: dendritic cells as a sufficient, but transient, source. J Immunol 2013; 190: 881-885.
23. Glabinski AR, Tuohy VK, Ransohoff RM,. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 1998; 5: 166-171.
24. Simpson JE, Newcombe J, Cuzner ML, et al. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998; 84: 238-249.
25. Prodinger C, Bunse J, Kruger M, et al. CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol 2011; 121: 445-458.
26. Karpus WJ, Lukacs NW, McRae BL, et al. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995; 155: 5003-5010.
27. Bailey-Bucktrout SL, Caulkins SC, Goings G, et al. Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis. J Immunol 2008; 180: 6457-6461.
28. Schwab N, Zozulya AL, Kieseier BC, et al. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis. J Immunol 2010; 184: 5368-5374.
29. Greter M, Heppner FL, Lemos MP, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005; 11: 328-334.
30. Centonze D, Muzio L, Rossi S, et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009; 29: 3442-3452.
31. Hebel K, Rudolph M, Kosak B, et al. IL-1beta and TGF-beta act antagonistically in induction and differentially in propagation of human proinflammatory precursor CD4+ T cells. J Immunol 2011; 187: 5627-5635.
32. Skarica M, Wang T, McCadden E, et al. Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis. J Immunol 2009; 182: 4192-4199.
33. Chiba K, Kataoka H, Seki N, et al. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-beta in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol 2011; 11: 366-372.
34. Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005; 2: 439-448.
35. Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011; 208: 2291-2303.
36. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011; 17: 604-609.